You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Managing Patients With R/R Multiple Myeloma: Stepping Up Care in the BCMA Era

  • Authors: Philippe Moreau, MD; Hermann Einsele, MD; Ajay K. Nooka, MD, MPH, FACP; Rakesh Popat, MD
  • CPD Released: 12/21/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 12/21/2022
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematologists, oncologists, and other healthcare providers caring for patients with relapsed/refractory multiple myeloma (R/R MM).

The goal of this activity is to provide hematologists/oncologists and other members of the healthcare team with clinically relevant knowledge and competence to help optimize the use of B-cell maturation antigen (BCMA)-targeted therapies in their patients with R/R MM.

Upon completion of this activity, participants will:

  • Have greater competence related to
    • Selecting an appropriate BCMA-targeted therapy for a patient with R/R MM
    • Managing adverse events associated with BCMA-targeted therapy in patients with R/R MM
  • Demonstrate greater confidence in their ability to
    • Integrate BCMA-targeted therapies into the management of patients with R/R MM


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Philippe Moreau, MD

    Professor of Clinical Hematology
    Head, Hematology Department
    University Hospital of Nantes
    Nantes, France

    Disclosures

    Disclosure: Philippe Moreau, MD, has the following relevant financial relationships:
    Advisor or consultant for: AbbVie; Amgen; Celgene; Janssen; Oncopeptides; Sanofi

  • Hermann Einsele, MD

    Director, Internal Medicine II
    University Hospital of Würzburg
    Würzburg, Germany

    Disclosures

    Disclosure: Hermann Einsele, MD, has the following relevant financial relationships:
    Advisor or consultant for: Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Sanofi
    Speaker or a member of a speakers bureau for: Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda
    Grants for clinical research from: Amgen; Bristol Myers Squibb Company; Celgene; Janssen

  • Ajay K. Nooka, MD, MPH, FACP

    Associate Professor
    Department of Hematology and Medical Oncology
    Medical Director
    Winship Data and Technology Applications Shared Resource
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia, United States

    The opinions expressed are those of Dr Nooka and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Nooka’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Disclosures

    Disclosure: Ajay K. Nooka, MD, MPH, FACP, has the following relevant financial relationships:
    Advisor or consultant for: Adaptive; Amgen; Bristol Myers Squibb Company; Janssen; Karyopharm; Oncopeptides; Sanofi; Takeda
    Grants for clinical research from: Amgen; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen; Karyopharm; Pfizer; Roche; Takeda

  • Rakesh Popat, MD

    Consultant Haematologist
    University College Hospital
    NHS Foundation Trust
    London, United Kingdom

    Disclosures

    Disclosure: Rakesh Popat, MD, has the following relevant financial relationships:
    Advisor or consultant for: Amgen; GlaxoSmithKline; Janssen
    Speaker or a member of a speakers bureau for: AbbVie; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen
    Grants for clinical research from: GlaxoSmithKline

Editor

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Sanneke Koekkoek (Enter degrees…), has disclosed no relevant financial relationships.

Content Reviewer

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Managing Patients With R/R Multiple Myeloma: Stepping Up Care in the BCMA Era

Authors: Philippe Moreau, MD; Hermann Einsele, MD; Ajay K. Nooka, MD, MPH, FACP; Rakesh Popat, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 12/21/2021

Valid for credit through: 12/21/2022

processing....

Educational Impact Challenge

The goal of this activity is to provide hematologists/oncologists and other members of the healthcare team with clinically relevant knowledge and competence to help optimize the use of B-cell maturation antigen (BCMA)-targeted therapies in their patients with R/R MM.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print